Skip to content
Third-party HPLC + mass spec on every lot
Verified — all release criteria met
released

Certificate of analysis

Cagrilintide

Lot CP-CAGRILP6-2604B · 10 mg

99.41 %

HPLC purity

Spec ≥ 98.0 %

88.9 %

Net peptide content

By amino acid analysis

< 0.30

Endotoxin (EU/mg)

Spec < 5.0 EU/mg

Provenance

Testing laboratory
Janoshik Analytical
Accreditation
ISO/IEC 17025:2017
Country of synthesis
United States
Manufactured
Apr 11, 2026
Release tested
Apr 20, 2026 (5 months ago)
Retest date
Apr 10, 2028
CAS number
1415456-99-3
Molecular formula
C194H310N50O61S2
Theoretical mass
4444.10 Da
Observed mass (LC-MS)
4443.96 Da (Δ 0.14 Da)

Assay results

Every line the release panel ran for this lot, with the method, the acceptance criterion and the measured value — not a pass mark alone.

Certificate of analysis — assay results
MethodParameterSpecificationResult
RP-HPLC (UV 214 nm)Purity (area %)≥ 98.0 %99.41 %Pass
LC-MS (ESI+)Identity — observed mass4444.10 ± 1.0 Da4443.96 DaPass
Amino acid analysisNet peptide content≥ 80.0 %88.9 %Pass
Karl FischerWater content≤ 8.0 %4.57 %Pass
Ion chromatographyResidual TFA≤ 1.0 %0.19 %Pass
LAL kinetic chromogenicBacterial endotoxin< 5.0 EU/mg< 0.30 EU/mgPass
USP <71> membrane filtrationSterilityNo growthNo growthPass
Visual / USP <790>AppearanceWhite to off-white cake, free of visible particulatesConformsPass

Handling for this lot

Appearance
White lyophilised powder
Storage
-20 °C lyophilised. Reconstituted stock is stable 2–8 °C for up to 21 days.
Reconstitution
Use a diluent at or above neutral pH. Acidic diluents measurably shorten solution stability.

Other lots of Cagrilintide

Compare batch to batch. Consistency across lots is a stronger signal than any single certificate.

Research use only. This certificate describes material supplied strictly for laboratory research. It is not a drug, food, cosmetic or medical device, has not been evaluated by the FDA, and is not intended for human or veterinary administration of any kind.